Among the various 3D culture approaches, spheroids and tumoroids have emerged as crucial tools for drug screening in preclinical and early clinical studies.
These models provide a better representation of tumor heterogeneity, cell-cell interactions, and drug penetration dynamics compared to traditional 2D cultures.
Spheroids are formed by self-assembly of cancer cells, mimicking avascular tumor structures, while tumoroids incorporate additional elements of the tumor-microenvironment, including stromal and immune components.
Their ability to preserve functional aspects of tumor biology allows for more accurate prediction of therapeutic efficacy and resistance mechanisms.
By offering a balance between complexity and reproducibility, these models are becoming indispensable for pre-clinical stages in drug development.
Advanced 3D patient-derived models for in-house use
Preclinical Drug Testing - Functional Assays
Our functional ex vivo killing assays use advanced 3D cancer models to help pharma teams reliably evaluate, quantify, and compare drug efficacy across cancer types, treatment candidates, and dose levels – providing standardized, actionable data to support drug development decisions.
Minimal Response: 25
Early Response: 25
Moderate Response : 25
Strong Response: 25
Early Response: 10
Moderate Response: 25
Strong Response: 25
Minimal Response: 5
Early Response: 25
Moderate Response : 25
Strong Response: 25
Early Response: 25
Moderate Response : 25
Strong Response: 25
Early Response: 15
Moderate Response : 25
Strong Response: 25
Strong Response: 25
Strong Response: 25